LONDON - Arrow Therapeutics Ltd. landed its first deal, licensing A-60444, a small-molecule inhibitor of respiratory syncytial virus, to Novartis Pharma AG for a $10 million down payment and $217 million linked to development milestones, followed by royalties. (BioWorld International)
LONDON - Arrow Therapeutics Ltd. landed its first deal, licensing A-60444, a small-molecule inhibitor of respiratory syncytial virus, to Novartis Pharma AG for a $10 million down payment and $217 million linked to development milestones, followed by royalties. (BioWorld Today)
LONDON - Arrow Therapeutics Ltd. landed its first deal, licensing A-60444, a small-molecule inhibitor of respiratory syncytial virus, to Novartis Pharma AG for a $10 million down payment and $217 million linked to development milestones, followed by royalties. (BioWorld Today)
LONDON - Microscience Ltd. is being acquired by U.S. company Emergent BioSolutions Inc. in an all-paper deal that values the vaccine specialist at £40 million (US$73.1 million), roughly £5 million less than the four venture capital investors have put in to date. (BioWorld International)
